SciSparc Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SPRC research report →
Price Chart
About the company
SciSparc Ltd. is a pharmaceutical company in the clinical development phase, specializing in creating medications derived from cannabinoid molecules. Their therapeutic pipeline encompasses several key drug candidates: SCI-110, which is being investigated for the treatment of Tourette syndrome, obstructive sleep apnea, and agitation associated with Alzheimer's disease; SCI-160, designed to address pain; and SCI-210, targeting autism spectrum disorder and epilepsy.
- CEO
- Oz Adler
- IPO
- 2021
- Employees
- 3
- HQ
- Tel Aviv, TA, IL
Get TickerSpark's AI analysis on SPRC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $113.58K
- P/E
- -0.00
- PEG
- -0.00
- P/S
- 0.16
- P/B
- 0.03
- EV/EBITDA
- 0.38
- Div Yield
- 0.00%
- Gross Margin
- 64.51%
- Op Margin
- -660.53%
- Net Margin
- -1210.90%
- ROE
- -200.93%
- ROIC
- -30.29%
Latest fiscal year · YoY change
- Revenue
- $856.00K-34.5%
- Gross Profit
- $631.00K+24.7%
- Op Income
- $-8,749,000
- Net Income
- $-12,179,000-93.8%
- EPS
- $-882.64-8980.7%
- OCF Growth
- +18.9%
- FCF Growth
- +18.9%
- 52W High
- $29.88
- 52W Low
- $0.17
- 50D MA
- $2.52
- 200D MA
- $5.02
- Beta
- 2.66
- RSI (14)
- 15
- Avg Volume
- 2.93M
No earnings-call transcripts are available for SPRC yet.
- Free Float
- 96.6%
- Shares Outstanding
- 580.97K
- Float Shares
- 561.12K
of shares held by institutions
7 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Jane Street Group, LLC | 13.97K | ▼ 2.52K |
| Hrt Financial LP | 13.72K | ▼ 7.52K |
| Citadel Advisors LLC | 11.06K | ▲ 11.06K |
| Ubs Group AG | 1.73K | ▼ 2.79K |
| Morgan Stanley | 200 | 0 |
| Jpmorgan Chase & Co | 13 | ▼ 198 |
Held by 7 ETFs
Biggest fund positions in SPRC by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 18, 26 | Adler Oz | other | 0 |
| Jan 3, 22 | Adler Oz | other | 0 |
| Mar 18, 26 | Revach Moshe | other | 0 |
| Jan 3, 22 | Revach Moshe | other | 0 |
| Mar 18, 26 | Shay Amnon Ben | other | 0 |
| Jan 3, 22 | Shay Amnon Ben | other | 0 |
| Mar 18, 26 | DAYAN ALON | other | 0 |
| Jan 3, 22 | DAYAN ALON | other | 0 |
| Mar 18, 26 | Sidi Liat | other | 0 |
| Jan 3, 22 | Sidi Liat | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SPRC coverage
Recent articles, reports, and earnings notes.
No research on SPRC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SPRC report →SciSparc: Former National Security Advisor to Prime Minister Benjamin Netanyahu Renowned AI Prof. Jacob Nagel Joins the Company's SAB
globenewswire.com · Nov 16
SciSparc: Subsidiary NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome
globenewswire.com · Oct 22
SciSparc Shifts Focus to Agentic AI, Targeting Cybersecurity and Finance Applications
globenewswire.com · Oct 19
SciSparc Shares Halted On Circuit Breaker To The Downside, Stock Now Down -23.69%
benzinga.com · Oct 15
SciSparc Announces Transformation into Agentic AI-Powered Technologies, Including Cybersecurity and Finance Technologies
globenewswire.com · Oct 15
SciSparc: Subsidiary NeuroThera Labs' CliniQuantum Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations Using Real-World Clinical Data on an S&P 500 Company's Quantum Architecture
globenewswire.com · Oct 7
SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations
globenewswire.com · Sep 23
SciSparc Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies
thenewswire.com · Sep 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.